4 курс / Акушерство и гинекология / Копылова_Ю_В_Роль_проангиогенных_и_антиангиогенных_факторов_в_развитии

vascularity.Am J Reprod Immunol. 2004 Apr;51(4):257-68. Review.

131. Unger EF, Goncalves L, Epstein SE et al. Effects of a single intracoronary injection of basic fibroblast growth factor in stableangina pectoris. Am J Cardiol 2000; 85: 1414–9.

132. Vatten, LJ. Is pre-eclampsia more than one disease / Vatten LJ., Skjaerven R // BJOG. 2004. - №111(4). – Р.298-302.

133.Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D'Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006. – №12. – Р.642–649.

134.Vigil-De Gracia P, Montufar-Rueda C, Ruiz J: Expectant management of severe preeclampsia and preeclampsia superimposed on chronic hypertension between 24 and 34 weeks' gestation. Eur J Obstet Gynecol Reprod Biol. 2003. – Р. 107-124.

135.Vigil-De Gracia P., Montufar-Reuda C., Smith A. Pregnancy and severe chronic chronic hypertension: maternal outcome// Hypertens. Pregnancy. 2004.-23(3).-P.285-293.

136.Vikse BE, Irgens LM, Leivestad T, Skjaerven R, Iversen BM. Preeclampsia and the risk of end-stage renal disease. N Engl J Med. –

2008. - №359. – Р. 800–809.

137.Villar J, Betran AP, Gulmezoglu M. Epidemiological basis for the planning of maternal health services. WHO/RHR. 2001.

138.Villar J, Say L, Gulmezoglu AM, Merialdi M, Lindheimer M, Beltran AP et al. Eclampsia and preeclampsia: a worldwide health problem for 2000 years. In Critchley H, Maclean A, Poston L, Walker J, eds. Preeclampsia, London: RCOG, 2003.

139.Von Dadelszen P., Ornstein M. P., Bull S. В., Logan A. G., Koren G., Magee L. A. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis//The Lancet. – 2000. - №

131

355. –Р. 87-92.

140.Wallner, W. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction / Wallner W, Sengenberger R, Strick R, Strissel PL, Meurer B, Beckmann MW, Schlembach D // Clin Sci (Lond). 2007. - №112(l). – Р.51-57.

141.Wathen, KA. Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or

intrauterine growth retardation / Wathen KA, Tuutti E, Stenman

UH, Alfthan H, Halmesmaki E, Finne P, Ylikorkala O, Vuorela P // J Clin Endocrinol Metab.2006. - №91. – P.180–184.

142.Wiliams, M.A. Plasma Tumor Necrosis Factor-a Solube Receptor p55 (sTNF p55) Concentration in Eclamptic, Preeclamptic and Normotensive Pregnant Women / Wiliams M.A., Mahomed K., Farrand A. et al.11th World Congress of the International Society for the Study of Hypertension in Pregnancy. – 2010. – P.572.

143.Willett, CG. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer / Willett CG, Boucher Y, di Tomaso E et al. // Nat Med. - 2004. -№10. - P. 145–7.

144.Wilson, B.I. Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results nom cohort study II / Wilson B.I., Watson M.S., Prescott O.I. et al. BMJ. 2003.-V.326.-

P.845.

145.Witlin, AG. The effect of magnesium sulfate therapy on the duration of labor in women with mild preeclampsia at term: a randomized, double-blind, placebo-controlled trial / Witlin, AG. Friedman SA, Sibai BM // Am J Obstet Gynecol. - 1997. №176(3). – P.623-7.

146.Wolf, M. Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies / Wolf M, Shah A, Lam C, Martinez A, Smirnakis KV, Epstein FH, Taylor RN, Ecker JL,

132

Karumanchi SA, Thadhani R // Am J Obstet Gynecol. - 2005. - №193.

– P.16-22.

147.Wulff, C. Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor Trap R1R2. 116. Wulff C, Wilson H, Wiegand SJ, Rudge JS, Fraser HM. Endocrinology. - 2002. - №143. P. 2797–2807.

148.Yu, L. Interaction between bevacizumab and murine VEGF-A: a reassessment131/ Yu L, Wu X, Cheng Z, Lee CV, LeCouter J, Campa C, Fuh G, Lowman H, Ferrara N. // Invest Ophthalmol Vis Sci. – 2008. - №49(2). – P.522-527.

149.Zhou, Y. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated / Zhou, Y., Mc. Master, M., Woo, K., Janatpour, M., Perry, J., Karpanen, T., Alitalo, K., Damsky, C. and Fisher, S. J. // Am. J. Pathol. — 2002. -

№3. – P. 33-37.

150. Zygmynt, M. Angiogenesis and vasculogenesis in prehnancy 119 / M Zygmynt, Herr P., Munstedt K. et al. Obstst Gynecol. - 2003. - №110.

– P.10-18

133